Trial Profile
SYNTAX Study: SYNergy Between PCI With TAXUS and Cardiac Surgery.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SYNTAX; SYNTAX-LE-MANS
- Sponsors Boston Scientific Corporation
- 22 Jun 2022 Results of post-hoc analysis assessing whether long-term clinical outcomes differ following percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in patients with three-vessel disease (3VD) and lesions in the proximal left anterior descending artery (P-LAD) published in the Heart
- 19 Apr 2022 Results assessing the ability of the 5-year major adverse cardiovascular event (MACE) model to predict treatment benefit of CABG vs PCI in the SYNTAX and BEST trials published in the Journal of the American College of Cardiology.
- 24 Mar 2022 Results published in the European Journal of Cardio-Thoracic Surgery